Optimizing second-line therapy for chronic myeloid leukemia.
Loading...
Date
2012-01
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Treatment of chronic myeloid leukemia has evolved from symptom control to long-term disease-free survival with cure potentially round the corner. This required faster, deeper, and longer response. Optimizing treatment decisions therefore requires clear understanding of and strict implementation of guidelines for shift from imatinib. In patients who are resistant to or intolerant of imatinib, second-line TKIs have to be selected carefully. Currently available data show comparable efficacy between nilotinib and dasatinib. With a better safety profile (especially with respect to grade 3 or 4 hematologic toxicity and clinically relevant non-hematologic toxicities), nilotinib becomes the preferred choice in most instances.
Description
Keywords
Dasatinib, imatinib intolerance, mutation, nilotinib, resistance, toxicity
Citation
Raja T. Optimizing second-line therapy for chronic myeloid leukemia. Indian Journal of Cancer. 2012 Jan-Mar; 49(1): 46-56.